|
[1]WAI CT, GREENSON JK, FONTANA RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C[J]. Hepatology, 2003, 38 (2) :518-526.
|
|
[2]VALLET-PICHARD A, MALLET V, NALPAS B, et al. FIB-4:An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest[J]. Hepatology, 2007, 46 (1) :32-36.
|
|
[3]HUI AY, CHAN HL, WONG VW, et al. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model[J]. Am J Gastroenterol, 2005, 100 (3) :616-623.
|
|
[4]ZENG MD, LU LG, MAO YM, et al. Prediction of significant fibrosis in HBe Ag-positive patients with chronic hepatitis B by a noninvasive model[J]. Hepatology, 2005, 42 (6) :1437-1445.
|
|
[5]CASTERA L. Non-invasive tests for liver fibrosis progression and regression[J]. J Hepatol, 2016, 64 (1) :232-233.
|
|
[6]SHIFFMAN ML, STERLING RK, CONTOS M, et al. Long term changes in liver histology following treatment of chronic hepatitis C virus[J]. Ann Hepatol, 2014, 13 (4) :340-349.
|
|
[7]VILAR-GOMEZ E, CALZADILLA-BERTOT L, FRIEDMAN SL, et al. Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH[J]. Liver Int, 2017, 37 (12) :1887-1896.
|
|
[8]POYNARD T, MCHUTCHISON J, MANNS M, et al. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin[J]. Hepatology, 2003, 38 (2) :481-492.
|
|
[9]POYNARD T, MOUSSALLI J, MUNTEANU M, et al. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C[J]. J Hepatol, 2013, 59 (4) :675-683.
|
|
[10]DONG XQ, WU Z, ZHAO H, et al. Evaluation and comparison of thirty noninvasive models for diagnosing liver fibrosis in chinese hepatitis B patients[J]. J Viral Hepat, 2018.[Epub ahead of print]
|
|
[11]KIM WR, BERG T, ASSELAH T, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients[J]. J Hepatol, 2016, 64 (4) :773-780.
|
|
[12]D'AMBROSIO R, AGHEMO A, RUMI MG, et al. A morphometric and immune-histochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis[J]. Hepatology, 2012, 56:532-543.
|
|
[13]EL-RAZIKY M, KHAIRY M, FOUAD A, et al. Effect of direct-acting agents on fibrosis regression in chronic hepatitis C virus patients'treatment compared with interferon-containing regimens[J]. J Interferon Cytokine Res, 2018, 38 (3) :129-136.
|
|
[14]DOLMAZASHVILI E, ABUTIDZE A, CHKHARTISHVILI N, et al. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia:Results of hepatology clinic HEPA experience[J]. Eur J Gastroenterol Hepatol, 2017, 29 (11) :1223-1230.
|
|
[15]BRUNO S, CROSIGNANI A, FACCIOTTO C, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus–induced cirrhosis. A 12-year prospective follow-up study[J]. Hepatology, 2010, 51 (6) :2069-2076.
|
|
[16]TANWAR S, TREMBLING PM, HOGAN BJ, et al. Noninvasive markers of liver fibrosis:On-treatment changes of serum markers predict the outcome of antifibrotic therapy[J]. Eur J Gastroenterol Hepatol, 2017, 29 (3) :289-296.
|
|
[17]KARSDAL MA, HJULER ST, LUO Y, et al. Assessment of liver fibrosis progression and regression by a serological collagen turnover profile[J]. Am J Physiol Gastrointest Liver Physiol, 2018.[Epub ahead of print]
|
|
[18]LEEMING DJ, VEIDAL SS, KARSDAL MA, et al. Pro-C5, a marker of true type V collagen formation and fibrillation, correlates with portal hypertension in patients with alcoholic cirrhosis[J]. Scand J Gastroenterol, 2015, 50 (5) :584-592.
|
|
[19]MARCELLIN P, ZIOL M, BEDOSSA P, et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B[J]. Liver Int, 2009, 29 (2) :242-247.
|
|
[20]LI Y, HUANG YS, WANG ZZ, et al. Systematic review with meta-analysis:The diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B[J]. Aliment Pharmacol Ther, 2016, 43 (4) :458-469.
|
|
[21]CHON YE, PARK JY, MYOUNG SM, et al. Improvement of liver fibrosis after long-term antiviral therapy assessed by fibroscan in chronic hepatitis B patients with advanced fibrosis[J]. Am J Gastroenterol, 2017, 112 (6) :882-891.
|
|
[22]OMAR H, SAID M, ELETREBY R, et al. Longitudinal assessment of hepatic fibrosis in responders to direct-acting antivirals for recurrent hepatitis C after liver transplantation using noninvasive methods[J]. Clin Transplant, 2018, 32 (8) :e13334.
|
|
[23]LIANG X, XIE Q, TAN D, et al. Interpretation of liver stiffness measurement based approach for the monitoring of hepatitis B patients with antiviral therapy:A 2-year prospective study[J]. J Viral Hepat, 2018, 25 (3) :296-305.
|
|
[24]KIM BS, SEO YS, KIM YS, et al. Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis[J]. J Gastroenterol Hepatol, 2018, 33 (2) :503-510.
|
|
[25]MAURO E, CRESPO G, MONTIRONI C, et al. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C[J]. Hepatology, 2018, 67 (5) :1683-1694.
|
|
[26]LENS S, ALVARADO-TAPIAS E, MARIO Z, et al. Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis[J]. Gastroenterology, 2017, 153 (5) :1273-1283.
|
|
[27]D'AMBROSIO R, AGHEMO A, FRAQUELLI M, et al. The diagnostic accuracy of FibroScan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response[J]. J Hepatol, 2013, 59 (2) :251-256.
|
|
[28]WANLESS IR, NAKASHIMA E, SHERMAN M. Regression of human cirrhosis morphologic features and the genesis of incomplete septal cirrhosis[J]. Arch Pathol Lab Med, 2000, 124 (11) :1599-1607.
|
|
[29]BEDOSSA P. Reversibility of hepatitis B virus cirrhosis after therapy:Who and why?[J]. Liver Int, 2015, 35 (Suppl 1) :78-81.
|
|
[30]HYTIROGLOU P, THEISE ND. Regression of human cirrhosis:An update, 18 years after the pioneering article by Wanless et al[J]. Virchows Arch, 2018, 473 (1) :15-22.
|
|
[31]LIU SB, IKENAGA N, PENG ZW, et al. Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits spontaneous fibrosis reversal in mice[J].FASEB J, 2016, 30 (4) :1599-1609.
|
|
[32]IKENAGA N, PENG ZW, VAID KA, et al. Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal[J]. Gut, 2017, 66 (9) :1697-1708.
|
|
[33]ZHAO W, YANG A, CHEN W, et al. Inhibition of lysyl oxidase-like 1 (LOXL1) expression arrests liver fibrosis progression in cirrhosis by reducing elastin crosslinking[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864 (4 Pt A) :1129-1137.
|
|
[34]SUN Y, ZHOU J, WANG L, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment[J]. Hepatology, 2017, 65 (5) :1438-1450.
|
|
[35]WANG B, SUN Y, ZHOU J, et al. Advanced septa size quantitation determines the evaluation of histological fibrosis outcome in chronic hepatitis B patients[J]. Mod Pathol, 2018, 31 (10) :1567-1577.
|
DownLoad: